Default company panoramic image
Ddb9fc72 3662 4623 a173 18d8d8c155b7


ReavillMED is a FDA 510K approved technology that provides a simple way to catheterize the human heart to ascertain patient condition. Once a peripheral IV cat

  • Stage Not Set
  • Industry Not Set
  • Location Plainfield, IL, USA
  • Currency USD
  • Website

Company Summary

There are 750,000 Septic patients per year with a 35% mortality rate. Additionally, central line associated blood stream infections result in 30,000 to 62,000 deaths per year. The ReavillMED System is the key enabling element for Early Goal Directed Therapy to be started in the Emergency Department for the detection and treatment of sepsis. The ReavillMED System is self-contained and thus not exposed during insertion thereby reducing infection.


  • Default avatar
    Matthew Reavill
    President & CEO

    Matthew invented the ReavillMED catheter. Matthew's father died from a Central Venous Line infection. Matthew has 22 years of healthcare experience mainly related to infusion disposables. He has a background in sales for both established and startup companies with emphasis on selling new and innovative medical products. He has extensive knowledge on the application and use of medical products. Education consists of Industrial Technology.

  • Default avatar
    Johnathan Macy

    Johnathan has over 28 years of healthcare experience comprised of medical devices. Background includes roles in business leadership, operations, product R&D and process technology. He served as Sr. Vice President, for Becton Dickinson a Fortune 500 medical healthcare company with revenue over $7 billion. His most recent role has been the Chief Operating Officer for Facet Technologies. Education consists of Mechanical Engineering and a MBA.